The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel
Betsy Rolland PhD, MLIS, MPH1,2, Sarah D. Hohl MPH, PhD1, Mara Minion MA1, Robert Adsit MEd3, Margaret B. Nolan MD, MS3, 4, Danielle Pauk BS1, Steven L. Bernstein MD5, Jessica L. Burris PhD6, Paul M. Cinciripini PhD7, Anne Joseph MD, MPH8, Jamie Ostroff PhD9, Graham W. Warren MD, PhD10, and Michael C. Fiore MD, MPH, MBA1, 3
1 Carbone Cancer Center, School of Medicine and Public Health; | 2 Institute for Clinical and Translational Research; | 3 Department of Medicine, Center for Tobacco Research and Intervention, School of Medicine and Public Health; and | 4 Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; | 5 Department of Emergency Medicine, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire; | 6 Department of Psychology and Markey Cancer Center, University of Kentucky, Lexington, Kentucky; | 7 Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas; | 8 Department of Medicine, University of Minnesota, Minneapolis, Minnesota; | 9 Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York; and | 10 Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina.
Submitted July 26, 2021; final revision received September 14, 2021; accepted for publication September 16, 2021.
Disclosures: P.M. Cinciripini has disclosed receiving nonmonetary research support from Pfizer. G.W. Warren has disclosed participating in research for the Agency for Healthcare Research and Quality and serving as a consultant for the Canadian Partnership Against Cancer. The remaining individuals have disclosed no relevant financial relationships.
Funding: This supplement was funded by the C3I Coordinating Center contract from the National Cancer Institute (CRDF Award #66590). In addition, authors received funding for their C3I participation via a supplement to their NCI P30 cancer center support grant during the period 2017–2021.